磷脂酰胆碱涂层局部递送抗菌药物并在小鼠模型中减少感染:一项初步研究
本研究评估磷脂酰胆碱涂层同时递送阿米卡星与顺-2-癸烯酸(C2DA)的体外洗脱特性及在小鼠假体周围感染模型中的体内效果;体外洗脱显示1至2天爆发释放、C2DA低水平释放持续至第4天,体内各组均实现植入物表面完全清除,但骨内清除比例组间差异有统计学意义。
要点
- 磷脂酰胆碱涂层在磷酸盐缓冲液中可洗脱阿米卡星和C2DA达4天。
- 含25%阿米卡星或15%阿米卡星联合任意量C2DA的洗脱液可抑制金黄色葡萄球菌。
- 小鼠模型中各治疗组植入物表面均完全清除细菌,骨内清除比例组间差异有统计学意义。
核心结论
- 磷脂酰胆碱涂层在体外无限下沉条件下于磷酸盐缓冲液中洗脱抗菌药物长达4天,并在初步体内模型中减少细菌菌落。
- 含不同量C2DA和阿米卡星的洗脱液浊度试验结果与既往显示二者协同作用的研究一致。
研究设计与样本
- 体外洗脱研究:评估含0%、5%、15%、25%重量比阿米卡星和C2DA所有混合物的涂层在7天内的洗脱效果(n=4),采用定量高效液相色谱测定浓度并绘制浓度-时间曲线。
- 体外抗菌活性:通过过夜浊度试验检测洗脱样本对金黄色葡萄球菌或铜绿假单胞菌的活性。
- 体内疗效:使用磷脂酰胆碱涂层金属丝植入物的小鼠感染模型(n=3),植入物分别涂有含无抗菌药物、单用阿米卡星、单用C2DA或阿米卡星联合C2DA的磷脂酰胆碱,插入每只小鼠股骨髓腔并接种金黄色葡萄球菌,1周后测定植入物表面及周围骨内活菌菌落数。
主要发现
- 洗脱样本显示阿米卡星和C2DA在1至2天内出现爆发释放,C2DA以低水平持续释放至第4天。
- 所有测试的洗脱样本均抑制铜绿假单胞菌。
- 含25%阿米卡星或15%阿米卡星联合任意量C2DA的涂层洗脱样本能够抑制金黄色葡萄球菌形成,而所有含5%阿米卡星或15%阿米卡星但不含C2DA的涂层无抑制作用。
- 体内所有治疗组均实现金属丝植入物表面完全细菌清除;单用C2DA和单用阿米卡星涂层清除了骨内所有菌落(植入物:仅磷脂酰胆碱组3例中1例;阿米卡星组3例中3例,C2DA组3例中3例,阿米卡星联合C2DA组3例中3例,p=0.04[Fisher精确检验];骨:仅涂层组3例中0例;阿米卡星组3例中3例;C2DA组3例中3例;C2DA联合阿米卡星组3例中1例;p=0.03[Fisher精确检验])。
关键数值与推荐
- 体外洗脱研究加载浓度包括0%、5%、15%、25%重量比的阿米卡星和C2DA所有混合物(n=4)。
- 含25%阿米卡星或15%阿米卡星联合任意量C2DA的洗脱样本抑制金黄色葡萄球菌;含5%阿米卡星或15%阿米卡星但不含C2DA的样本无抑制作用。
- 植入物完全清除比例:仅磷脂酰胆碱组3例中1例,阿米卡星组3例中3例,C2DA组3例中3例,阿米卡星联合C2DA组3例中3例,p=0.04(Fisher精确检验)。
- 骨内完全清除比例:仅涂层组3例中0例,阿米卡星组3例中3例,C2DA组3例中3例,C2DA联合阿米卡星组3例中1例,p=0.03(Fisher精确检验)。
临床怎么用
- 作者指出,作为全身治疗的辅助手段,载C2DA的磷脂酰胆碱涂层有潜力作为预防性感染预防措施。
- 作者提出未来研究可能包括不同抗生素、更大样本量和更多对照的动物研究以及先进涂层递送方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phosphatidylcholine coatings have been shown to elute antibiotics for several days. A recently developed biofilm inhibitor, cis-2-decenoic acid (C2DA), has been shown to exhibit synergistic activity with several common antibiotics. This study aims to evaluate the effectiveness of C2DA and amikacin dual drug delivery from a phosphatidylcholine coating. QUESTIONS/PURPOSES: (1) What are the in vitro elution profiles of amikacin and C2DA from phosphatidylcholine-coated coupons in incubated phosphate-buffered saline? (2) Does the presence of C2DA in eluate samples lower the amount of amikacin needed for bacterial inhibition in overnight bacterial turbidity assays? (3) Does addition of amikacin and C2DA result in decreased colony-forming units (CFUs) on wire implants and bone when compared with phosphatidylcholine coatings alone in a mouse model of periprosthetic joint infection? METHODS: Effects of loading concentrations were assessed during 7-day in vitro elution studies for coatings containing all mixtures of 0%, 5%, 15%, and 25% wt of amikacin and C2DA (n = 4) through quantitative high-performance liquid chromatography concentration determination and plotting concentration eluted over time. Antimicrobial activity was assessed by overnight turbidity testing of elution study samples against Staphylococcus aureus or Pseudomonas aeruginosa. In vivo efficacy was assessed using phosphatidylcholine-coated wire implants in a murine (mouse) model of infection (n = 3). Wire implants were coated with phosphatidylcholine containing no antimicrobials, amikacin alone, C2DA alone, or amikacin and C2DA and then inserted into the intramedullary femur of each mouse and inoculated with S aureus. The number of viable bacterial colonies on the implant surface and in the surrounding bone was determined after 1 week with the goal of achieving complete bacterial clearance. Total viable CFU count and proportion of samples achieving complete clearance were compared between groups. RESULTS: Elution samples showed a burst response of amikacin and C2DA for 1 to 2 days with C2DA release continuing at low levels through Day 4. All tested eluate samples inhibited P aeruginosa. Samples from coatings containing 25% amikacin or 15% amikacin and any amount of C2DA were able to inhibit S aureus formation, but all coatings with 5% amikacin or 15% amikacin but no C2DA were not inhibitory. All in vivo treatment groups achieved complete bacterial clearance on the wire implant, and the C2DA alone and amikacin alone coatings cleared all CFUs in bone (pin: phosphatidylcholine only one of three; amikacin three of three, C2DA three of three, amikacin + C2DA three of three, p = 0.04 [Fisher's exact test]; bone: coating only: zero of three; amikacin: three of three; C2DA; three of three; C2DA + amikacin: one of three; p = 0.03 [Fisher's exact test]). CONCLUSIONS: Phosphatidylcholine coatings elute antimicrobials in vitro under infinite sink conditions for up to 4 days in phosphate-buffered saline and were able to reduce bacterial colonies in a preliminary in vivo model. Turbidity testing with eluate samples containing varying amounts of C2DA and amikacin agrees with previous studies showing synergy between them. CLINICAL RELEVANCE: Used as an adjunctive to systemic therapy, C2DA-loaded phosphatidylcholine coatings have potential value as a prophylactic infection prevention measure. Future studies may include different antibiotics, animal studies with larger sample sizes and more controls, and advanced coating delivery methods.
引用
- Harris MA, Beenken KE, Smeltzer MS, et al. Phosphatidylcholine Coatings Deliver Local Antimicrobials and Reduce Infection in a Murine Model: A Preliminary Study. Clin Orthop Relat Res. 2017. PMID: 28050817. doi:10.1007/s11999-016-5211-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。